GSK, Amgen and AstraZeneca released positive data supporting their rival drugs in a condition called chronic rhinosinusitis ...

Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...

Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania, according to a statement in the company’s ...

M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.

Frazier Life Sciences and a cadre of well-known biotech investors are coming together for a new startup in the antibody-drug ...

Neumora pauses two Phase 3 trials of navacaprant for depression after earlier trial failure, CEO Paul Berns makes changes to ...

For years, artificial intelligence has been a topic of discussion in pharmaceutical manufacturing, but adoption has been slow ...

The higher prices of two COPD inhalers from GSK that are targeted in the second round of government drug price negotiations ...

AbbVie becomes an obesity contender as it partners with Danish biotech Gubra in $350M upfront deal for amylin analog GUBamy, ...

Lexicon's non-opioid drug pilavapadin fails Phase 2b pain trial at 20mg dose, but shows promise at 10mg. Company plans Phase ...

Nuvation Bio gets $250M total funding for taletrectinib commercialization & pipeline; Syros to delist from Nasdaq on March 20 after January compliance warning ...

Biotech investing saw growth in 2024, with RA Capital leading VCs. FDA cancels flu vaccine meeting, Pfizer hires ex-FDA ...